Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies

Stock Information for Martin Midstream Partners L.P.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Martin Midstream Partners L.P.

Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy
Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Caribou Biosciences to Participate in Upcoming Investor Conferences
Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025
Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
Caribou Biosciences to Participate in Upcoming Investor Conferences

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.